Product
Nanatinostat
Aliases
Nanatinostat (free base) tablets in combination with Valganciclovir, Nanatinostat mesylate tablets in combination with Valganciclovir, Single-agent Nanatinostat (free base) tablets, VRx-3996
2 clinical trials
6 indications
Indication
Advanced CancerIndication
Nasopharyngeal CarcinomaIndication
EBV-Associated Gastric CarcinomaIndication
Epstein-Barr Virus Related CarcinomaIndication
Epstein-Barr Virus Related SarcomaClinical trial
A Phase 1 Study to Investigate the Mass Balance of [14C]-Nanatinostat and to Evaluate the Relative Bioavailability of Nanatinostat in Patients With Selected Advanced CancersStatus: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
An Open-Label, Multicenter Phase 1b/2 Study of Nanatinostat and Valganciclovir in Patients With Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors and in Combination With Pembrolizumab in Patients With Recurrent/Metastatic Nasopharyngeal CarcinomaStatus: Recruiting, Estimated PCD: 2024-12-01